RxDoctor Payments DataLook up a doctor →

Tracy Dobbs, MD

Medical Oncology · Knoxville, TNNPI 1104826148

Payments from drug & device makers

$536,265in general payments, 2019–2025

Across 1,451 payments — averaging $369.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$224K
  • Pfizer$155K
  • Janssen Research & Development, LLC$55K
  • Merck Healthcare Kgaa$45K
  • Jazz Pharmaceuticals Inc.$18K
  • AstraZeneca$11K
  • plus $26K from 54 others

What the payments were for

  • Consulting fees$2,0868%
  • Food & beverage$23,61091%
  • Education$3701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beigene, Ltd.57$224,282
Pfizer77$155,432
Janssen Research & Development, LLC10$54,637
Merck Healthcare Kgaa23$45,341
Jazz Pharmaceuticals Inc.22$18,113
AstraZeneca(2 entities)89$11,410
Amgen81$5,272
Sanofi49$2,896
E.r. Squibb & Sons, L.L.C.129$1,698
Novartis80$1,616
Johnson & Johnson(2 entities)77$1,346
Merck77$1,334
Daiichi Sankyo Inc.48$1,042
Genentech USA, Inc.53$871
Gilead(2 entities)33$650
Eisai Inc.34$622
Bristol Myers Squibb36$594
Astellas Pharma US Inc37$586
Incyte Corporation34$552
Bayer26$498
Exelixis Inc.26$498
GSK25$490
Seagen Inc.31$458
AbbVie19$358
Lilly USA, LLC18$350
Regeneron Healthcare Solutions, Inc.15$294
Takeda Pharmaceuticals U.S.A., Inc.15$275
EMD Serono, Inc.14$253
Mckesson Drug Company LLC2$253
Karyopharm Therapeutics Inc.11$241
Pharmacyclics LLC, An Abbvie Company13$210
Rigel Pharmaceuticals, Inc.11$209
Beigene USA, Inc.10$191
Ipsen Biopharmaceuticals, Inc10$189
Pharmacosmos Therapeutics Inc.8$163
Puma Biotechnology, Inc.9$156
AVEO Pharmaceuticals, Inc.5$152
Sobi, Inc7$147
Mirati Therapeutics, Inc.5$144
Morphosys, US Inc.5$119
Galvanize Therapeutics, Inc1$116
Boehringer Ingelheim6$113
Secura Bio, Inc.9$112
Tersera Therapeutics LLC5$109
Array Biopharma Inc6$92
Teva Pharmaceuticals USA, Inc.6$90
Sanofi-aventis U.S. LLC1$85
Stemline Therapeutics Inc.4$80
Genmab U.S., Inc.3$69
Novocure Inc.4$66
Sun Pharmaceutical Industries Inc.3$65
EUSA Pharma (US) LLC4$63
Springworks Therapeutics, Inc.2$62
Heron Therapeutics, Inc.2$62
Beone Medicines USA, Inc.3$59
Coherus Oncology, Inc.3$59
Progenics Pharmaceuticals, Inc.1$56
Foundation Medicine, Inc.3$51
Taiho Oncology, Inc.4$49
Tolmar Pharmaceuticals, Inc.3$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$536,265 in reported general payments places this provider in the 70th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,702,152
Medicare patients
622
Services billed
231,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeytrudaPembrolizumab36$405,518
Lenalidomide24$375,426
TagrissoOsimertinib Mesylate20$328,503
IclusigPonatinib Hcl13$284,581
PomalystPomalidomide12$270,886
XtandiEnzalutamide14$198,735
BrukinsaZanubrutinib12$169,944
IbrancePalbociclib11$157,633
TasignaNilotinib Hcl11$111,520
AranespDarbepoetin Alfa In Polysorbat13$37,030
Imatinib Mesylate24$30,069
Anastrozole84$1,115
Hydroxyurea25$514
Ondansetron OdtOndansetron38$479
Prochlorperazine Maleate36$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckKeytruda$1,334$405,51836 claims
AstraZenecaTagrisso$11,410$328,50320 claims
Takeda Pharmaceuticals U.S.A., Inc.Iclusig$275$284,58113 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,698$270,88612 claims
Astellas Pharma US IncXtandi$586$198,73514 claims
Beigene USA, Inc.Brukinsa$191$169,94412 claims
PfizerIbrance$155,432$157,63311 claims
NovartisTasigna$1,616$111,52011 claims
AmgenAranesp$5,272$37,03013 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$90$9313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →